Saint Charles, Missouri, United States
NCT Number: NCT00926926
Effects of Oxybutynin Topical Gel on Gastric Emptying
This study explores the effect of oxybutynin topical gel on gastric emptying
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
Female
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Adult, healthy, post-menopausal females
Exclusion criteria
- Patients for whom OTG or acetaminophen is contraindicated.
- Abnormality of the GI tract.
- Taking drugs that affect gastric motility.
Treatment and study plan
Oxybutynin Chloride Gel
DrugOnce daily for 7 days, followed by single dose of acetaminophen
Placebo Gel
DrugOnce daily for 7 days, followed by single dose of acetaminophen
Primary outcomes
-
The effect of oxybutynin chloride topical gel administration on gastric emptying will be assessed by comparing the single dose relative bioavailability of acetaminophen
Time frame: After 7 days of treatment
Sponsors and collaborators
Lead sponsor
Watson Pharmaceuticals
Industry
Registry information
Official study title
Effect of Oxybutynin Chloride Topical Gel on Gastric Emptying, Using the Acetaminophen Absorption Test
Important dates
- Study start
- 2009
- Primary completion
- 2009
- Study completion
- 2009
- First posted
- Jun 24, 2009
- Registry last updated
- Oct 8, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAI Chatbot for HPV Vaccine Literacy Among Caregivers in Japan
NCT06702423
Healthy
London, United Kingdom
View Trial DetailsValidation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
NCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNormative Value for Navicular Drop Test in Older Adults
NCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details